CliffBio
biologic

Cimzia

certolizumab pegol

Loss of exclusivityApril 2020projected — 12-year biologic exclusivity estimate
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameCimzia
Active ingredientcertolizumab pegol
Strength200MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2008
Marketing statusRx

More from UCB

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cimzia patent cliff — loss of exclusivity April 2020 | CliffBio